<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225796</url>
  </required_header>
  <id_info>
    <org_study_id>00044216</org_study_id>
    <nct_id>NCT01225796</nct_id>
  </id_info>
  <brief_title>Study of Sodium Bicarbonate in Kidney Transplant Recipients</brief_title>
  <official_title>Randomized Trial of Sodium Bicarbonate in Renal Transplant Recipients With Low-normal Serum Bicarbonate Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of sodium bicarbonate versus no sodium&#xD;
      bicarbonate treatment on urinary ammonia levels and urinary transforming growth factor-beta1&#xD;
      (TGF-beta1) excretion in renal transplant patients with low-to-normal serum bicarbonate&#xD;
      levels (20 - 28 mmol/L).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Renal allograft survival ten years after transplant is only about 50%. In people with&#xD;
      non-transplant chronic kidney disease (CKD), sodium bicarbonate treatment seems to delay&#xD;
      progressive decline in kidney function in those with low serum bicarbonate levels (metabolic&#xD;
      acidosis). This may be because sodium bicarbonate reduces renal ammonia production and hence&#xD;
      fibrosis. Observational evidence suggests that people with CKD and low-normal serum&#xD;
      bicarbonate levels might also benefit from sodium bicarbonate treatment. TGF-beta1 levels&#xD;
      seem to be an important predictor of chronic allograft nephropathy, and alkalinizing agents&#xD;
      may have an effect on TFG-beta1 excretion.&#xD;
&#xD;
      Retrospective analysis of participants in the African American Study of Kidney Disease and&#xD;
      Hypertension showed the lowest risk of CKD progression was among those having baseline serum&#xD;
      bicarbonate levels in the range of 28-30 mmol/L. Recent studies in people with pre-transplant&#xD;
      CKD have suggested that increasing low serum bicarbonate levels (&lt; 22 mmol/L) with&#xD;
      alkalinizing agents such as sodium bicarbonate and sodium citrate may reduce CKD progression.&#xD;
&#xD;
      Design: this is an open-label randomized study testing the effect of a six-month intervention&#xD;
      with sodium bicarbonate 650 mg orally thrice daily versus no sodium bicarbonate treatment on&#xD;
      renal ammonia excretion and urinary TGF-beta1.&#xD;
&#xD;
      Visits will occur at baseline, 3 months, and 6 months. At each follow-up visit, the study&#xD;
      coordinator or principal investigator will review a medical questionnaire with the&#xD;
      participant and collect a sample of blood and urine for analysis of urinary TGF-beta1,&#xD;
      metabolic panel, pH, urinary net acid excretion, urinary bicarbonate and urinary ammonia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary transforming growth factor-beta1</measure>
    <time_frame>6 months</time_frame>
    <description>This is considered a surrogate marker of chronic allograft nephropathy (tubulointerstitial fibrosis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>urinary ammonia excretion</measure>
    <time_frame>6 months</time_frame>
    <description>a component of urinary acid excretion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive oral sodium bicarbonate 650mg three times daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will not receive any sodium bicarbonate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium bicarbonate</intervention_name>
    <description>Sodium bicarbonate 650mg by mouth three times daily for 6 months.</description>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Renal transplant recipients&#xD;
&#xD;
          -  Age 21-75 years&#xD;
&#xD;
          -  Six months since the time of the most recent transplant&#xD;
&#xD;
          -  Serum bicarbonate 20-28mM on the two most recent serum measures with the last six&#xD;
             months&#xD;
&#xD;
          -  Stable creatinine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systolic blood pressure &gt; 140mmHg&#xD;
&#xD;
          -  Diastolic blood pressure &gt; 90mmHg&#xD;
&#xD;
          -  Known ejection fraction &lt;50%&#xD;
&#xD;
          -  Clinical diagnosis of heart failure&#xD;
&#xD;
          -  Use of &gt;3 antihypertensive agents&#xD;
&#xD;
          -  &gt; 1+ edema&#xD;
&#xD;
          -  Use of alkali in the preceding 3 months&#xD;
&#xD;
          -  History of noncompliance with clinic visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kalani L Raphael, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009 Sep;20(9):2075-84. doi: 10.1681/ASN.2008111205. Epub 2009 Jul 16.</citation>
    <PMID>19608703</PMID>
  </reference>
  <reference>
    <citation>Amara AB, Sharma A, Alexander JL, Alfirevic A, Mohiuddin A, Pirmohamed M, Close GL, Grime S, Maltby P, Shawki H, Heyworth S, Shenkin A, Smith L, Sharma AK, Hammad A, Rustom R. Randomized controlled trial: lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy. Transplantation. 2010 Jan 15;89(1):104-14. doi: 10.1097/TP.0b013e3181bf13d9.</citation>
    <PMID>20061926</PMID>
  </reference>
  <reference>
    <citation>Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int. 2010 Aug;78(3):303-9. doi: 10.1038/ki.2010.129. Epub 2010 May 5.</citation>
    <PMID>20445497</PMID>
  </reference>
  <reference>
    <citation>Raphael KL, Wei G, Baird BC, Greene T, Beddhu S. Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney Int. 2011 Feb;79(3):356-62. doi: 10.1038/ki.2010.388. Epub 2010 Oct 20.</citation>
    <PMID>20962743</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>October 15, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Kalani Raphael</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bicarbonate</keyword>
  <keyword>Chronic allograft nephropathy</keyword>
  <keyword>Urinary TGF-beta</keyword>
  <keyword>Urinary acid excretion</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

